ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China flag China · Delayed Price · Currency is CNY
7.54
-0.14 (-1.82%)
Jul 30, 2026, 3:04 PM CST

SHE:300254 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
17.824.8542.1925.2-118.52-91.44
Depreciation & Amortization
58.4158.4158.2558.5364.7966.93
Other Amortization
2.952.951.020.850.750.74
Loss (Gain) From Sale of Assets
-8.94-8.94-7.51-18.8-0.690.37
Asset Writedown & Restructuring Costs
0.430.435.675.5148.431.68
Loss (Gain) From Sale of Investments
-3.97-3.97-4.54-20.883.43-13.64
Provision & Write-off of Bad Debts
5.085.085.78-0.430.71-5.32
Other Operating Activities
99.5576.5652.6456.1268.9373.92
Change in Accounts Receivable
-40.67-40.67-71.14-5.35-120.83119.48
Change in Inventory
-2.3-2.3-28.39-20.613.816.31
Change in Accounts Payable
-36.67-36.6713.4-40.02123.41-91.56
Change in Other Net Operating Assets
24.1724.1713.48---
Operating Cash Flow
112.7196.7770.9437.8174.8896.92
Operating Cash Flow Growth
177.53%36.41%87.60%-49.50%-22.75%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-33.08-34.32-51.5-33.92-26.78-36.93
Sale of Property, Plant & Equipment
0.930.350.21100.832.126.42
Divestitures
--1.63---0.27
Investment in Securities
-147.41-60.29-202.845.191.475.57
Other Investing Activities
3.62.364.23---
Investing Cash Flow
-175.97-91.89-248.2772.1-23.2-25.21

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--1.8---
Long-Term Debt Issued
-286.3321.62115.75271.6100.9
Total Debt Issued
315.8286.3323.42115.75271.6100.9
Short-Term Debt Repaid
---1.8---
Long-Term Debt Repaid
--305.08-144.7-138.74-223.42-218.32
Total Debt Repaid
-288.09-305.08-146.5-138.74-223.42-218.32
Net Debt Issued (Repaid)
27.71-18.78176.93-22.9948.18-117.42
Issuance of Common Stock
43.9643.9633.35-105.25-
Repurchase of Common Stock
-0.29-0.29-1.66-203.24--
Common Dividends Paid
-18.09-18.97-12.32-13.31-11.9-14.67
Other Financing Activities
60.551-1.45-2.23-28.96-20.21
Financing Cash Flow
113.856.93194.84-241.77112.56-152.3

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
50.5911.817.51-131.85164.24-80.58

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
79.6362.4519.443.948.0959.99
Free Cash Flow Growth
200.81%221.25%398.72%-91.90%-19.84%-
Free Cash Flow Margin
9.23%7.17%2.30%0.49%5.80%6.45%
Free Cash Flow Per Share
0.320.260.080.020.200.26
Levered Free Cash Flow
116.85170.49-82.9-157.05316.5823.16
Unlevered Free Cash Flow
129.99184.01-72.29-136.33345.3753.89

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
128.73125.2996.53116.4589.1789.28
Change in Working Capital
-58.59-58.59-82.56-68.287.0733.67